BRPI0411552A - sclerostin-specific antibodies and methods to increase bone mineralization - Google Patents

sclerostin-specific antibodies and methods to increase bone mineralization

Info

Publication number
BRPI0411552A
BRPI0411552A BRPI0411552-0A BRPI0411552A BRPI0411552A BR PI0411552 A BRPI0411552 A BR PI0411552A BR PI0411552 A BRPI0411552 A BR PI0411552A BR PI0411552 A BRPI0411552 A BR PI0411552A
Authority
BR
Brazil
Prior art keywords
methods
sclerostin
bone
specific antibodies
tgf
Prior art date
Application number
BRPI0411552-0A
Other languages
Portuguese (pt)
Inventor
David G Winkler
Jiye Shi
John Latham
Original Assignee
Celltech R & D Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech R & D Inc filed Critical Celltech R & D Inc
Publication of BRPI0411552A publication Critical patent/BRPI0411552A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)

Abstract

"ANTICORPOS ESPECìFICOS A ESCLEROSTINA E MéTODOS PARA AUMENTAR A MINERALIZAçãO óSSEA". São propostas composições e métodos referentes a anticorpos que se ligam especificamente a proteínas de ligação a TGF-<225>. Estes métodos e composições se referem à alteração da densidade mineral óssea por interferência na interação entre a proteína esclerostina que se liga a TGF-<225> e um membro da superfamília de TGF-<225>, especialmente uma proteína morfogênica óssea. O aumento da densidade mineral óssea tem emprego em condições e doenças em que a baixa densidade mineral óssea tipifica a condição, tais como osteopenia, osteoporose e fraturas ósseas."SPECIFIC ANTIBODIES FOR SCLEROSTIN AND METHODS FOR INCREASING BONE MINERALIZATION". Antibody compositions and methods are proposed which specifically bind to TGF-β binding proteins. These methods and compositions refer to the alteration of bone mineral density by interfering with the interaction between the TGF-β binding sclerostin protein and a member of the TGF-β superfamily, especially a bone morphogenic protein. Increased bone mineral density is used in conditions and diseases where low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.

BRPI0411552-0A 2003-06-16 2004-06-15 sclerostin-specific antibodies and methods to increase bone mineralization BRPI0411552A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47897703P 2003-06-16 2003-06-16
PCT/US2004/018912 WO2005014650A2 (en) 2003-06-16 2004-06-15 Antibodies specific for sclerostin and methods for increasing bone mineralization

Publications (1)

Publication Number Publication Date
BRPI0411552A true BRPI0411552A (en) 2006-08-01

Family

ID=34135049

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411552-0A BRPI0411552A (en) 2003-06-16 2004-06-15 sclerostin-specific antibodies and methods to increase bone mineralization

Country Status (17)

Country Link
US (12) US7381409B2 (en)
EP (1) EP1636270B1 (en)
JP (2) JP4688802B2 (en)
KR (1) KR101210187B1 (en)
CN (1) CN1835974A (en)
AU (1) AU2004262640B2 (en)
BR (1) BRPI0411552A (en)
CA (1) CA2529623A1 (en)
EA (1) EA015166B1 (en)
ES (1) ES2586401T3 (en)
IL (1) IL172598A0 (en)
ME (1) MEP2808A (en)
NO (1) NO345763B1 (en)
NZ (1) NZ544618A (en)
RS (1) RS20050934A (en)
WO (1) WO2005014650A2 (en)
ZA (1) ZA200600388B (en)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009535A1 (en) * 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
ES2639020T3 (en) 1998-11-27 2017-10-25 Ucb Pharma S.A. Compositions and methods to increase bone substance mineralization
WO2003087763A2 (en) 2002-04-03 2003-10-23 Celltech R & D, Inc. Association of polymorphisms in the sost gene region with bone mineral density
US7585501B2 (en) 2002-06-14 2009-09-08 Stowers Institute For Medical Research Compositions and methods for treating kidney disease
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
US20040023356A1 (en) * 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
CN1835974A (en) * 2003-06-16 2006-09-20 细胞技术研究与发展公司 Antibodies specific for sclerostin and methods for increasing bone mineralization
US8461155B2 (en) * 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US9046537B2 (en) 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
JP2008507288A (en) 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ActRII receptor polypeptides, methods, and compositions
ITMI20050739A1 (en) * 2005-04-22 2006-10-23 Effebi Spa VALVE-ACTUATOR CONNECTION PLATE
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) * 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
AU2012238247B2 (en) * 2005-05-03 2016-06-16 Amgen, Inc. Sclerostin binding agents
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
BRPI0618947B1 (en) 2005-11-23 2022-07-19 Acceleron Pharma Inc ACTRIIA POLYPEPTIDE THAT BINDS ACTIVIN, POLYNUCLEOTIDE ISOLATED, POLYNUCLEOTIDE, RECOMBINANT, METHOD FOR PREPARING AN ACTRIIA POLYPEPTIDE THAT BINDS ACTIVIN, PHARMACEUTICAL PREPARATION AND USE OF AN ACTRIIA-FC FUSION PROTEIN TO PROMOTE BONE GROWTH AND INHIBITS BONE RESORPTION
WO2008133722A2 (en) * 2006-11-10 2008-11-06 Ucb Pharma S.A. Anti human sclerostin antibodies
US20100036091A1 (en) * 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
SI3345607T1 (en) 2006-12-29 2023-03-31 Ossifi-Mab Llc Methods of altering bone growth by administration of sost or wise antagonist or agonist
TWI584815B (en) 2007-02-01 2017-06-01 艾瑟勒朗法瑪公司 Activin-ActRIIa antagonist and its use for treating or preventing breast cancer
TW201627320A (en) 2007-02-02 2016-08-01 艾瑟勒朗法瑪公司 Variants derived from ActRIIB and their uses
MX2009008510A (en) 2007-02-09 2010-01-15 Acceleron Pharma Inc Activin-actriia antagonists and uses for promoting bone growth in cancer patients.
EP2131860B1 (en) 2007-03-20 2013-12-18 Eli Lilly & Company Anti-sclerostin antibodies
KR101703299B1 (en) * 2007-06-01 2017-02-06 오픈 모노클로날 테크놀로지, 인코포레이티드 Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
CL2008002775A1 (en) 2007-09-17 2008-11-07 Amgen Inc Use of a sclerostin binding agent to inhibit bone resorption.
CA2699936A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
AR068767A1 (en) 2007-10-12 2009-12-02 Novartis Ag ANTIBODIES AGAINST SCLEROSTIN, COMPOSITIONS AND METHODS OF USE OF THESE ANTIBODIES TO TREAT A PATHOLOGICAL DISORDER MEDIATIONED BY SCLEROSTIN
AU2008338464A1 (en) 2007-12-14 2009-06-25 Amgen Inc. Method for treating bone fracture with anti-sclerostin antibodies
US8071914B2 (en) * 2007-12-26 2011-12-06 Noboru Oshima Heating apparatus
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
DK3750552T5 (en) 2008-08-14 2024-08-26 Acceleron Pharma Inc GDF TRAPS
AU2010204985A1 (en) 2009-01-13 2011-08-04 Acceleron Pharma Inc. Methods for increasing adiponectin
CN102548617B (en) * 2009-03-30 2017-11-07 阿塞勒隆制药公司 BMP‑ALK3 antagonists and uses for promoting bone growth
WO2010115932A1 (en) 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
WO2010130830A2 (en) * 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders
MX355042B (en) 2009-06-08 2018-04-02 Acceleon Pharma Inc Methods for increasing thermogenic adipocytes.
CN107267520A (en) 2009-06-12 2017-10-20 阿塞勒隆制药公司 The ACTRIIB FC fusion proteins of truncation
ES2658292T3 (en) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses thereof with respect to the induction of utrophin for the treatment of muscular dystrophy
MX2012011629A (en) 2010-04-07 2013-03-05 Abbvie Inc Tnf-î± binding proteins.
EP2558106A1 (en) 2010-04-16 2013-02-20 Novartis AG Methods and compositions for improving implant osseointegration
SMT202000095T1 (en) 2010-05-14 2020-03-13 Amgen Inc High concentration anti-sclerostin antibody formulations
WO2011147193A1 (en) * 2010-05-27 2011-12-01 The University Of Hong Kong High-affinity nucleic acid aptamers against sclerostin protein
US9493541B2 (en) 2010-06-07 2016-11-15 Joshua Rabbani Antibodies specific for sulfated sclerostin
US9617323B2 (en) * 2010-06-07 2017-04-11 Joshua Rabbani Sulfonated sclerostin, antibodies, epitopes and methods for identification and use therefor
WO2011159826A2 (en) 2010-06-15 2011-12-22 Vertex Pharmaceuticals Incorporated Hcv ns5b protease mutants
CA2815416A1 (en) 2010-10-21 2012-04-26 Vertex Pharmaceuticals Incorporated Biomarkers for hcv infected patients
AU2011325134B2 (en) 2010-11-05 2014-10-23 Novartis Ag Methods of treating rheumatoid arthritis using IL-17 antagonists
CA2817008A1 (en) 2010-11-08 2012-05-18 Acceleron Pharma Inc. Actriia binding agents and uses thereof
JP2014509588A (en) 2011-03-01 2014-04-21 アムジエン・インコーポレーテツド Bispecific binding agent
US9145457B2 (en) 2011-03-25 2015-09-29 Amgen Inc. Sclerostin antibody crystals and formulations thereof
ES2823240T3 (en) 2011-04-19 2021-05-06 Amgen Inc Method for treating osteoporosis
US20140056912A1 (en) 2011-04-29 2014-02-27 Novartis Ag Methods of treating squamous cell carcinoma
ES2667554T3 (en) 2011-08-04 2018-05-11 Amgen Inc. Method for the treatment of bone space defects
UY34410A (en) 2011-10-24 2013-05-31 Abbvie Inc BISPECIFIC IMMUNOLIGANTS DIRECTED AGAINST TNF
AR088513A1 (en) 2011-10-24 2014-06-18 Abbvie Inc IMMUNO LINKERS AGAINST SCLEROSTINE
AU2012328921B2 (en) 2011-10-24 2017-05-11 Abbvie Inc. Immunobinders directed against TNF
KR20190120401A (en) 2011-12-28 2019-10-23 암젠 인크 Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
JP6770312B2 (en) 2012-07-05 2020-10-14 ユセベ ファルマ ソシエテ アノニム Treatment of bone diseases
WO2014015217A1 (en) 2012-07-19 2014-01-23 Vertex Pharmaceuticals Incorporated Biomarkers for hcv infected patients
RU2678117C2 (en) 2012-11-02 2019-01-23 Селджин Корпорейшн Activin-actrii antagonists and uses thereof for treating bone and other disorders
UY35148A (en) 2012-11-21 2014-05-30 Amgen Inc HETERODIMERIC IMMUNOGLOBULINS
WO2014118705A1 (en) 2013-01-31 2014-08-07 Novartis Ag Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
CN105307641A (en) 2013-05-03 2016-02-03 西莱克塔生物科技公司 Combinations of administration for reducing an undesired humoral immune response
CN103550785B (en) * 2013-10-30 2016-05-18 清华大学深圳研究生院 TGF-beta receptor is in conjunction with the purposes of albumen-1
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
CN114699529A (en) 2014-06-13 2022-07-05 阿塞勒隆制药公司 Methods and compositions for treating ulcers
MA41052A (en) 2014-10-09 2017-08-15 Celgene Corp TREATMENT OF CARDIOVASCULAR DISEASE USING ACTRII LIGAND TRAPS
EP3227675B1 (en) 2014-12-03 2023-03-15 Celgene Corporation Activin-actrii antagonists and uses for treating myelodysplastic syndrome
MA41142A (en) 2014-12-12 2017-10-17 Amgen Inc ANTI-SCLEROSTINE ANTIBODIES AND THE USE OF THEM TO TREAT BONE CONDITIONS AS PART OF THE TREATMENT PROTOCOL
AR103173A1 (en) 2014-12-22 2017-04-19 Novarits Ag PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF ANTIBODIES IL-17
WO2016145961A1 (en) 2015-03-13 2016-09-22 江苏恒瑞医药股份有限公司 Anti-sclerostin antibody, antigen binding fragment and medical use thereof
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
GB201609235D0 (en) 2016-05-25 2016-07-06 Univ Cape Town Production of a horseradish peroxidase-IGG fusion protein
GB201610044D0 (en) * 2016-06-08 2016-07-20 Ucb Biopharma Sprl Antibodies
MA45921A (en) 2016-08-08 2019-06-19 Amgen Inc METHOD OF IMPROVING CONNECTIVE TISSUE FIXATION USING ANTI-SCLEROSTINE ANTIBODIES.
US10961305B2 (en) 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
AU2017381433B2 (en) 2016-12-21 2024-11-14 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
CA3050715A1 (en) 2017-01-19 2018-07-26 Open Monoclonal Technology, Inc. Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
EP4599848A3 (en) 2017-03-11 2025-12-03 Cartesian Therapeutics, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
RU2647571C1 (en) * 2017-08-25 2018-03-16 Владимир Глебович Лунин Recombinant white scelestine, method for producing recombinant protein of screrostin, method of increasing bone mass of vertebrate animal
CN108101984B (en) * 2017-12-18 2019-10-15 中国人民解放军总医院 Preparation method and application of sclerostin single chain antibody
CN111712573B (en) 2018-02-12 2023-10-20 安沛治疗有限公司 Aptamer against sclerostin and use thereof
EP3774879B1 (en) 2018-03-30 2026-01-28 Amgen Inc. C-terminal antibody variants
GB201810746D0 (en) 2018-06-29 2018-08-15 Mereo Biopharma 3 Ltd Use of sclerostin antagonist
CA3108693A1 (en) 2018-08-10 2020-02-13 Ashutosh Sharma Method of preparing an antibody pharmaceutical formulation
US12553041B2 (en) 2019-06-04 2026-02-17 Cartesian Therapeutics Inc. Formulations and doses of pegylated uricase
WO2021030179A1 (en) 2019-08-12 2021-02-18 Amgen Inc. Anti-sclerostin antibody formulations
PH12023550779A1 (en) 2020-09-28 2023-11-20 Angitia Biomedicines Ltd Anti-sclerostin constructs and uses thereof
CN113214479B (en) * 2021-05-08 2022-03-18 四川大学 Mineralized anticarious material and its prepn
KR20260040623A (en) 2023-07-19 2026-03-25 암젠 인크 Method for preparing a buffer for therapeutic protein formulations

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4427115A (en) 1981-10-19 1984-01-24 Laipply Thomas C One piece alcohol preparation device
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
DE3417525C1 (en) 1984-05-11 1986-01-09 Matter + Siegmann Ag, Wohlen Device for the quantitative and qualitative detection of hydrocarbon-containing suspended particles in gases
JP2624470B2 (en) 1984-10-02 1997-06-25 バイオジェン インコーポレイテッド Production of streptavidin-like polypeptide
US5272254A (en) 1984-10-02 1993-12-21 Biogen Inc. Production of streptavidin-like polypeptides
SG64329A1 (en) 1984-11-16 1999-04-27 American Cyanamid Co Antitumor antibiotics (LL-E33288 complex)
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
GB8723661D0 (en) 1987-10-08 1987-11-11 British Bio Technology Synthetic gene
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
EP0313874B1 (en) 1987-10-30 1994-04-13 American Cyanamid Company Disulfur analogs of LL-E33288 antitumor agents
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
WO1990013361A1 (en) 1989-05-04 1990-11-15 Southern Research Institute Improved encapsulation process and products therefrom
KR920007887B1 (en) 1989-08-29 1992-09-18 스즈키 지도오샤 고오교오 가부시키가이샤 Exhaust gas cleaning device for internal combustion engine
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5177197A (en) 1990-02-27 1993-01-05 Ludwig Institute For Cancer Research Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
JP3218637B2 (en) 1990-07-26 2001-10-15 大正製薬株式会社 Stable aqueous liposome suspension
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
JP2958076B2 (en) 1990-08-27 1999-10-06 株式会社ビタミン研究所 Multilamellar liposome for gene transfer and gene-captured multilamellar liposome preparation and method for producing the same
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
JPH04141095A (en) 1990-10-02 1992-05-14 Chemo Sero Therapeut Res Inst Hiv-resistant recombined modified antibody and method for preparing modified antibody
US5070108A (en) 1990-10-12 1991-12-03 Trustees Of The University Of Pennsylvania Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal
WO1992006693A1 (en) 1990-10-22 1992-04-30 Fox Chase Cancer Center Dna construct for providing rna therapy
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US6072039A (en) 1991-04-19 2000-06-06 Rohm And Haas Company Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest
AU668349B2 (en) * 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
DE4135543A1 (en) 1991-10-28 1993-04-29 Boehringer Mannheim Gmbh RECOMBINANT CORE STREPTAVIDINE
EP0578515A3 (en) 1992-05-26 1995-05-10 Bristol Myers Squibb Co Humanized monoclonal antibodies.
EP0644938A1 (en) 1992-05-29 1995-03-29 E.I. Du Pont De Nemours And Company PRODUCTION OF STREPTAVIDIN FROM $i(BACILLUS SUBTILIS)
DE69418699T2 (en) 1993-01-11 1999-09-30 Dana-Farber Cancer Institute, Boston INDUCTION OF ANSWERS OF CYTOTOXIC T-LYMPHOCYTES
FR2702160B1 (en) 1993-03-02 1995-06-02 Biovecteurs As Synthetic particulate vectors and method of preparation.
FR2704145B1 (en) 1993-04-21 1995-07-21 Pasteur Institut Particulate vector and pharmaceutical composition containing it.
WO1994028929A1 (en) 1993-06-07 1994-12-22 Genentech, Inc. Hiv envelope polypeptides
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5453492A (en) 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
EP0756628B1 (en) 1994-04-29 2007-11-14 Curis, Inc. Morphogenic protein-specific cell surface receptors and uses therefor
FR2723849B1 (en) 1994-08-31 1997-04-11 Biovector Therapeutics Sa PROCESS FOR INCREASING IMMUNOGENICITY, PRODUCT OBTAINED AND PHARMACEUTICAL COMPOSITION
US5846770A (en) 1994-11-22 1998-12-08 Genetics Institute, Inc. DNA molecules encoding human chordin
US6057421A (en) 1994-11-30 2000-05-02 Immpheron, Inc. Variable heavy and light chain regions of murine monoclonal antibody 1F7
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
CA2220912A1 (en) 1995-06-05 1996-12-12 Gregg A. Hastings Human ccn-like growth factor
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
BR9710811A (en) 1996-05-22 1999-08-17 Novopharm Biotech Inc Antigen-binding fragments that specifically detect nucleotide cancer cells that encode the fragments and their use for the prophylaxis and detection of cancer
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US5989909A (en) 1997-09-26 1999-11-23 Millennium Biotherapeutics, Inc. Huchordin and uses thereof
WO1998046588A2 (en) 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
JP3614866B2 (en) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド Artificial antibody polypeptide
US6075007A (en) 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
EP1367124A1 (en) 1997-08-01 2003-12-03 Genset 5' ests for secreted proteins expressed in muscle and other mesodermal tissues
US6815201B2 (en) 1997-09-08 2004-11-09 The Public Health Research Institute Of The City Of New York, Inc. HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies
JP4480268B2 (en) 1998-02-12 2010-06-16 イミューン コンプレックス コーポレイション Strategically modified hepatitis B core proteins and their derivatives
GB9818881D0 (en) * 1998-08-28 1998-10-21 Glaxo Group Ltd Compounds
US6544485B1 (en) * 2001-01-29 2003-04-08 Sharper Image Corporation Electro-kinetic device with enhanced anti-microorganism capability
ES2639020T3 (en) 1998-11-27 2017-10-25 Ucb Pharma S.A. Compositions and methods to increase bone substance mineralization
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US6355271B1 (en) 1999-02-03 2002-03-12 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
ATE444971T1 (en) * 1999-06-09 2009-10-15 Genentech Inc COMPOSITIONS AND METHODS FOR TUMOR TREATMENT
JP4141095B2 (en) 1999-10-29 2008-08-27 三洋電機株式会社 Semiconductor device and manufacturing method thereof
AU4196801A (en) 2000-03-02 2001-09-12 Amgen Inc Chordin-like-2 molecules and uses thereof
EP1290169A2 (en) 2000-06-01 2003-03-12 Amgen, Inc. Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
JP2004520005A (en) 2000-06-19 2004-07-08 エフ．ホフマン−ラ　ロシュ　アーゲー Osteolevin gene polymorphism
CA2421056A1 (en) 2000-09-01 2002-03-28 Genentech, Inc. A polypeptide for use as a diagnostic marker for the presence of colon tumours
DE60139944D1 (en) 2000-10-12 2009-10-29 Genentech Inc LOW VISCOSIS CONCENTRATED PROTEIN FORMULATIONS
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CA2374027A1 (en) 2001-03-13 2002-09-13 The Minister Of National Defence Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee)
DE10145772A1 (en) 2001-09-17 2003-04-10 Bayer Cropscience Ag DELTA · 1 · -pyrrolines
JP4467304B2 (en) 2001-12-06 2010-05-26 バイオコントロール システムズ，インコーポレイティド Sample collection and testing system
US20030186915A1 (en) 2002-02-11 2003-10-02 Yang Pan Regulatory polynucleotides and uses thereof
WO2003073991A2 (en) 2002-03-01 2003-09-12 Celltech R & D, Inc. Methods to increase or decrease bone density
WO2003087763A2 (en) 2002-04-03 2003-10-23 Celltech R & D, Inc. Association of polymorphisms in the sost gene region with bone mineral density
US7893218B2 (en) * 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
US20040023356A1 (en) * 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
AU2003304107B2 (en) 2002-11-01 2008-05-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides
US7642238B2 (en) * 2002-12-05 2010-01-05 Shaughnessy John D Molecular determinants of myeloma bone disease and uses thereof
US20040141875A1 (en) * 2003-01-15 2004-07-22 Rajiv Doshi System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units
EP1608399B1 (en) 2003-03-14 2012-01-11 Ucb Manufacturing, Inc. Complex of sclerostin and noggin or chordin, and agents that modulate the formation of said complex
CU23403A1 (en) 2003-04-23 2009-08-04 Centro Inmunologia Molecular RECOMBINANT ANTIBODIES AND FRAGMENTS RECOGNIZING GANGLIOSIDE N-GLICOLIL GM3 AND ITS USE FOR DIAGNOSIS AND TUMOR TREATMENT
CN1835974A (en) * 2003-06-16 2006-09-20 细胞技术研究与发展公司 Antibodies specific for sclerostin and methods for increasing bone mineralization
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US8003108B2 (en) * 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
WO2008133722A2 (en) 2006-11-10 2008-11-06 Ucb Pharma S.A. Anti human sclerostin antibodies
US20100036091A1 (en) * 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
SI3345607T1 (en) 2006-12-29 2023-03-31 Ossifi-Mab Llc Methods of altering bone growth by administration of sost or wise antagonist or agonist
EP2114435A1 (en) 2007-02-02 2009-11-11 Novartis AG Modulators of sclerostin binding partners for treating bone-related disorders
EP2131860B1 (en) 2007-03-20 2013-12-18 Eli Lilly & Company Anti-sclerostin antibodies
CL2008002775A1 (en) 2007-09-17 2008-11-07 Amgen Inc Use of a sclerostin binding agent to inhibit bone resorption.
AR068767A1 (en) * 2007-10-12 2009-12-02 Novartis Ag ANTIBODIES AGAINST SCLEROSTIN, COMPOSITIONS AND METHODS OF USE OF THESE ANTIBODIES TO TREAT A PATHOLOGICAL DISORDER MEDIATIONED BY SCLEROSTIN
MX2010004761A (en) 2007-11-02 2010-05-19 Novartis Ag Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6).
AU2008338464A1 (en) 2007-12-14 2009-06-25 Amgen Inc. Method for treating bone fracture with anti-sclerostin antibodies

Also Published As

Publication number Publication date
ZA200600388B (en) 2008-06-25
US20110206677A1 (en) 2011-08-25
CA2529623A1 (en) 2005-02-17
NO20060236L (en) 2006-03-14
US20180072801A1 (en) 2018-03-15
US7868134B2 (en) 2011-01-11
WO2005014650A2 (en) 2005-02-17
US8992911B2 (en) 2015-03-31
US9657095B2 (en) 2017-05-23
US11702468B2 (en) 2023-07-18
EA200600038A1 (en) 2006-06-30
EP1636270A2 (en) 2006-03-22
US20120321636A1 (en) 2012-12-20
US9011856B2 (en) 2015-04-21
ES2586401T3 (en) 2016-10-14
EP1636270B1 (en) 2016-07-20
US20130064830A1 (en) 2013-03-14
JP2011105729A (en) 2011-06-02
JP4688802B2 (en) 2011-05-25
MEP2808A (en) 2010-02-10
US20200231664A1 (en) 2020-07-23
JP2007537130A (en) 2007-12-20
NO345763B1 (en) 2021-07-19
IL172598A0 (en) 2006-04-10
RS20050934A (en) 2008-04-04
US7381409B2 (en) 2008-06-03
US20240209075A1 (en) 2024-06-27
KR20060035622A (en) 2006-04-26
CN1835974A (en) 2006-09-20
US20150191537A1 (en) 2015-07-09
US20110195453A1 (en) 2011-08-11
EA015166B1 (en) 2011-06-30
US20090117118A1 (en) 2009-05-07
WO2005014650A3 (en) 2005-07-28
US20050106683A1 (en) 2005-05-19
US8563271B2 (en) 2013-10-22
US20130064829A1 (en) 2013-03-14
AU2004262640B2 (en) 2010-12-23
US20110206678A1 (en) 2011-08-25
NZ544618A (en) 2009-02-28
KR101210187B1 (en) 2012-12-07
AU2004262640A1 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
BRPI0411535A (en) compositions and methods for increasing bone mineralization
EA200600038A1 (en) ANTIBODIES SPECIFIC FOR SKLEROSTIN, AND METHODS OF INCREASING BONE MINERALIZATION
NO20091387L (en) Antibodies to bone morphogenic proteins and receptors thereof, methods for their use
BRPI0516105A (en) platelet-derived growth factor compositions and methods of using these
CY1112797T1 (en) COMPLICATED SCARSTEIN AND NOGIN OR CHORDIN, AND FACTORS REGULATING THE FORMATION OF A COMPOSITE PROJECT
BRPI0411020A (en) gene expression profile, methods of identifying wnt pathway modular agents, preparing a gene expression profile, screening a remodeling agent associated with bone loading, and reagents that bind to proteins that modulate bone remodeling and / or bone mineralization, treating a bone mineralization disease or disorder, modulating bone mineralization in a cell and bone mineralization and / or bone remodeling in a patient, and determining whether a compound or composition enhances the loading effect. activity in bone cell activity / function and / or mineralization, candidate agent for treating a low bone mass condition and composition
CU20100059A7 (en) ANTI-SCLEROSTIN ANTIBODIES AND FUNCTIONAL PROTEINS
ATE398676T2 (en) ANTAGONISTIC SELECTIVE BINDING AGENTS OF THE OSTEOPROTEGERIN BINDING PROTEIN
CY1116377T1 (en) Suspensions of Human Tyrosine Protein Phosphate and Methods of Use
ATE382053T1 (en) SYSTEM FOR ANTIBODIES EXPRESSION AND SYNTHESIS
BRPI0417684A (en) compound, pharmaceutical composition, and use of a compound
AR064456A1 (en) CD 44 ANTIBODIES
NO20082559L (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
BR0314095A (en) Catalyst for the production of light olefins
BRPI0416544A (en) gag binding protein
CL2011000010A1 (en) Monoclonal anti-beta-amyloid peptide antibody; polynucleotide that encodes it; hybridoma; Method of production; composition comprising it; use to treat diseases related to amyloid proteins; method of diagnosing them; and kit that includes it.
EA200601191A1 (en) CARE CARE PRODUCTS CONTAINING KERATIN
BRPI0606790A2 (en) isolated human antibody or antigen binding portion thereof, isolated polypeptide, composition, isolated nucleic acid, host cell expression vector, rabies vaccine, kit, use of an isolated human monoclonal antibody or antigen binding portion thereof, or an effective amount of a composition, a method for identifying an antibody or fragment thereof, antibody or fragment thereof, antibody or fragment thereof, and glycoprotein.
WO2007098198A3 (en) Modulation of bone formation
BRPI0810130A8 (en) BEVERAGE COMPOSITION, PROCESS FOR PRODUCING A BEVERAGE COMPOSITION, AND, USE OF A BEVERAGE COMPOSITION
BR0312521A (en) Methods for the separation and purification of fibrinogen and at least one other protein and for the co-purification of fibrinogen and factor xiii, use of immobilized metal ion affinity chromatography, fibrinogen, pharmaceutical kit, and pharmaceutical formulations and freeze-dried fibrinogen
EA200600539A1 (en) A METHOD FOR DETERMINING THE IMPACT OF A MULTI-COMPONENT MIXTURE OF NATURAL PRODUCTS ON THE BIOLOGICAL PROFILE OF DISEASES WITHIN THE GROUP OF LIVING SYSTEMS AND THE DEVELOPMENT AND CONTROL OF QUALITY OF MEDICINES IN THE SYSTEM OF LIVING SYSTEMS
BR0306826A (en) Non-Native Peptide, Isolated Nucleic Acid, Isolated Antibody, Pharmaceutical Composition and Kit for Prevention and Treatment of Crf2r Modulated Disease
BR0014183A (en) Pharmaceutical compositions and methods of using secreted frizzled related protein
BR0012478A (en) Aminothiazole derivatives, their pharmaceutical preparation and composition containing the same

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: CELLTECH RANDD, INC. (US)

Free format text: A FIM DE ATENDER A TRANSFERENCIA REQUERIDA ATRAVES DA PETICAO NO 020120010209/RJ DE 06/12/2012, E NECESSARIO APRESENTAR A GUIA REFERENTE A SEGUNDA TRANSFERENCIA.

B25A Requested transfer of rights approved

Owner name: DARWIN MOLECULAR CORPORATION (US)

B25A Requested transfer of rights approved

Owner name: UCB MANUFACTURING INC. (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.